Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Shares Up 4.4% – Here’s Why

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA – Get Free Report) rose 4.4% on Monday. The stock traded as high as $23.75 and last traded at $22.54. 35,776 shares changed hands during trading, a decline of 92% from the average daily volume of 433,881 shares. The stock had previously closed at $21.60.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on DMRA shares. HC Wainwright reaffirmed a “buy” rating and set a $45.00 price objective on shares of Damora Therapeutics, Inc. Common Stock in a research report on Tuesday, July 21st. Wedbush restated an “outperform” rating and issued a $40.00 price target on shares of Damora Therapeutics, Inc. Common Stock in a research note on Tuesday, September 29th. Weiss Ratings restated a “sell (d-)” rating on shares of Damora Therapeutics, Inc. Common Stock in a research note on Monday, September 14th. TD Cowen raised Damora Therapeutics, Inc. Common Stock to a “strong-buy” rating in a report on Monday, August 24th. Finally, Jefferies Financial Group assumed coverage on Damora Therapeutics, Inc. Common Stock in a research report on Monday, July 27th. They set a “buy” rating and a $50.00 price objective for the company. Three analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $46.38.

Read Our Latest Stock Report on DMRA

Damora Therapeutics, Inc. Common Stock Price Performance

The stock has a 50 day moving average of $21.91 and a two-hundred day moving average of $25.58. The stock has a market capitalization of $1.40 billion, a PE ratio of -16.00 and a beta of 1.52.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA – Get Free Report) last released its quarterly earnings data on Wednesday, November 4th. The company reported ($0.40) earnings per share for the quarter, beating the consensus estimate of ($0.52) by $0.12. As a group, research analysts predict that Damora Therapeutics, Inc. Common Stock will post -2.09 earnings per share for the current fiscal year.

Insider Transactions at Damora Therapeutics, Inc. Common Stock

In other Damora Therapeutics, Inc. Common Stock news, CEO Jennifer Jarrett acquired 12,500 shares of the stock in a transaction dated Friday, September 25th. The stock was acquired at an average price of $20.23 per share, with a total value of $252,875.00. Following the completion of the transaction, the chief executive officer directly owned 512,500 shares in the company, valued at approximately $10,367,875. This trade represents a 2.50% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 0.40% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Arizona State Retirement System acquired a new stake in Damora Therapeutics, Inc. Common Stock during the 2nd quarter valued at $260,000. Squarepoint Ops LLC purchased a new position in Damora Therapeutics, Inc. Common Stock in the 2nd quarter valued at about $303,000. Aquatic Capital Management LLC purchased a new position in Damora Therapeutics, Inc. Common Stock in the 3rd quarter valued at about $523,000. Seven Fleet Capital Management LP acquired a new stake in shares of Damora Therapeutics, Inc. Common Stock during the second quarter valued at about $7,398,000. Finally, Bellevue Group AG grew its stake in shares of Damora Therapeutics, Inc. Common Stock by 18.6% during the third quarter. Bellevue Group AG now owns 1,919,383 shares of the company’s stock valued at $40,844,000 after acquiring an additional 300,537 shares in the last quarter. 14.20% of the stock is owned by institutional investors and hedge funds.

Damora Therapeutics, Inc. Common Stock Company Profile

(Get Free Report)

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis.

Featured Articles

Receive News & Ratings for Damora Therapeutics Inc. Common Stock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Damora Therapeutics Inc. Common Stock and related companies with MarketBeat.com's FREE daily email newsletter.